Patents by Inventor Tinya Abrams
Tinya Abrams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220031657Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Tinya ABRAMS, Larry Alexander GAITHER
-
Patent number: 11179365Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.Type: GrantFiled: November 14, 2018Date of Patent: November 23, 2021Assignee: NOVARTIS AGInventors: Tinya Abrams, Larry Alexander Gaither
-
Publication number: 20210000810Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.Type: ApplicationFiled: May 7, 2020Publication date: January 7, 2021Inventors: Tinya Abrams, Larry Alexander Gaither
-
Publication number: 20200405875Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: June 4, 2020Publication date: December 31, 2020Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 10786578Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: July 27, 2015Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Patent number: 10695333Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.Type: GrantFiled: November 29, 2018Date of Patent: June 30, 2020Assignee: Novartis AGInventors: Tinya Abrams, Larry Alexander Gaither
-
Publication number: 20200129632Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: December 9, 2019Publication date: April 30, 2020Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 10626172Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: May 24, 2018Date of Patent: April 21, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20190194315Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: June 17, 2016Publication date: June 27, 2019Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Publication number: 20190167652Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.Type: ApplicationFiled: November 29, 2018Publication date: June 6, 2019Inventors: Tinya ABRAMS, Larry Alexander GAITHER
-
Publication number: 20190142796Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.Type: ApplicationFiled: November 14, 2018Publication date: May 16, 2019Inventors: Tinya ABRAMS, Larry Alexander GAITHER
-
Publication number: 20190119375Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: May 24, 2018Publication date: April 25, 2019Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Patent number: 10117953Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: October 3, 2016Date of Patent: November 6, 2018Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Publication number: 20180193475Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: July 27, 2015Publication date: July 12, 2018Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 10005836Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: November 13, 2015Date of Patent: June 26, 2018Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20180125996Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: August 30, 2017Publication date: May 10, 2018Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 9789203Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 12, 2014Date of Patent: October 17, 2017Assignee: Novartis AGInventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20170035905Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: October 3, 2016Publication date: February 9, 2017Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Patent number: 9498543Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 12, 2014Date of Patent: November 22, 2016Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Publication number: 20160137730Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: November 13, 2015Publication date: May 19, 2016Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
